[Conclusions. Tenofovir].
Mallolas
Josep
J
Servicio de Enfermedades Infecciosas, Hospital Clínic, IDIBAPS, Facultat de Medicina, Universitat de Barcelona, Barcelona, España. mallolas@clinic.ub.es
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics; D006678:HIV / Q000201:enzymology / Q000235:genetics; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D008107:Liver Diseases / Q000150:complications; D063065:Organophosphonates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D054303:HIV Reverse Transcriptase; D000225:Adenine